Pharma BD Deal Intelligence

Astellas Pharma Inc. / AI Proteins, Inc.

2026 · Licensing/Option · $400M · Complete

AI Proteins, Inc. and Astellas Pharma Inc. announced on 21 October 2026 a research collaboration and license agreement to discover and develop novel miniprotein-based therapeutics, valued at over $400 million in upfront and milestone payments plus royalties on net sales. AI Proteins will design and optimize de novo miniprotein candidates against targets selected by Astellas using its computational protein design platform, which builds small proteins from scratch rather than modifying nature-derived biologics. Astellas holds exclusive worldwide rights to resulting therapeutics and assumes responsibility for subsequent development, regulatory approval and commercialization. No specific targets, indications or development candidates were disclosed. NOTE: ingested at pending_review by bd-enrichment-2026-10-23.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Astellas Pharma Inc. deals